AcquisitionOther
NGM BIOPHARMACEUTICALS INC acquired target
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
NGM BIOPHARMACEUTICALS INC -> target · $1.55
All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, always led by biology and motivated by unmet patient need.
Open source record (SEC) ↗